ADC Therapeutics ADCT 深 沪
已收盘 08-28 16:00:00 美东时间
1.14
+0.020
+1.79%
华盛通- 最 高1.17
- 今 开1.11
- 成交量 257.79万股
- 最 低 1.07
- 昨 收 1.12
- 总市值 1.46亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 2.02%
- 52周最低 0.7796
- 委 比 -18.55%
- 总股本 1.28亿
- 历史最高 56.59
- 量 比 1.43
- 振 幅 8.93%
- 历史最低 0.3599
- 每 手 1
- 风险率 1.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
08-17 21:41
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
08-14 02:14
ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $19.248 million wh...
08-13 19:33
ADC Therapeutics Q2 Earnings Preview
ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate ...
08-13 03:06
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
The Russell 2000 opened the second half of 2026 pinned near a record around 3,000, going almost nowhere since the first half closed. Underneath that flat tape, seven small caps ripped 28% or more in just four trading sessions. The index, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), is comi...
07-22 03:52
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
ADC Therapeutics Ltd ($ADCT) announced an update on their ongoing clinical stud...
07-21 00:30
ADC Therapeutics Completes Enrollment In LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating ZYNLONTA In Combination With Bispecific Antibody Glofitamab In Patients With R/R Diffuse Large B-Cell Lymphoma
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug con...
06-30 19:19
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- A...
06-30 19:15
